OPKO Health, Inc. (NASDAQ:OPK) Receives $1.55 Consensus Price Target from Analysts

Shares of OPKO Health, Inc. (NASDAQ:OPK) have earned an average recommendation of “Hold” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $1.55.

A number of equities analysts recently issued reports on OPK shares. Barrington Research cut their target price on OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, January 22nd. Finally, Wall Street Zen cut OPKO Health from a “hold” rating to a “sell” rating in a report on Saturday, March 7th.

OPKO Health Price Performance

OPKO Health stock opened at $1.17 on Friday. The stock has a market capitalization of $888.11 million, a price-to-earnings ratio of -3.90 and a beta of 1.49. OPKO Health has a 52-week low of $1.10 and a 52-week high of $1.60. The stock’s 50 day moving average price is $1.19 and its two-hundred day moving average price is $1.31. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.52 and a current ratio of 3.97.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The company had revenue of $148.50 million for the quarter, compared to analysts’ expectations of $139.76 million. During the same period last year, the business earned $0.01 EPS. OPKO Health’s quarterly revenue was down 19.1% compared to the same quarter last year. On average, equities analysts predict that OPKO Health will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On OPKO Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Caprock Group LLC purchased a new stake in OPKO Health in the 3rd quarter valued at $26,000. Swiss Life Asset Management Ltd purchased a new stake in OPKO Health in the 3rd quarter valued at $30,000. Zacks Investment Management purchased a new stake in OPKO Health in the 4th quarter valued at $27,000. Savant Capital LLC purchased a new stake in OPKO Health in the 3rd quarter valued at $33,000. Finally, StoneX Group Inc. purchased a new stake in OPKO Health in the 4th quarter valued at $27,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.